A bill aimed at reforming Pennsylvania’s drug classification system has legislators and harm reduction experts split on the best approach to reduce overdose deaths and promote recovery efforts in the commonwealth.

The proposed amendment to the state’s Controlled Substance, Drug, Device and Cosmetic Act, SB959, passed 30-20 on Wednesday in the Pennsylvania Senate.

It would allow for automatic scheduling of new drugs to align with the federal Drug Enforcement Administration’s classification system. Sponsored by Sens. Devlin Robinson, R-Allegheny, and Lisa Baker, R-Luzerne, the bill’s memorandum states that the amendment will help the state keep abreast of a changing drug supply.

Supporters of SB959 see it as a single prong in a multi-pronged approach, which, for many, including Ms. Baker, still involves the support of harm reduction tools such as naloxone and drug testing strips.

Advertise with us

Those on the ground, however, feel the situation is too dire, and that legislators aren’t entrenched enough in communities impacted by addiction.

“As many experts you’re talking to, you should be talking to that many drug users or more,” said Jordan Scott, digital advocacy and organizing coordinator for the Pennsylvania Harm Reduction Network. “I’ve been at this 21 years, and I’m tired of burying my friends.”

With a Republican Senate majority of 28-22, two Democrats voted “yes” on the bill; all those who voted “no” were Democrats.

The legislation was referred to the House Judiciary Committee on Wednesday. If approved, it will go to a Democratic-controlled House for a vote, before landing on the governor’s desk. House Judiciary chair Tim Briggs, D-Montgomery, declined to comment on account of the bill’s nascence.

“As we’re battling the opioid pandemic, all too frequently we see new drugs enter the market,” said bill co-sponsor Mr. Robinson. “We have a lengthy rule-making process in Pennsylvania, and it can take years to add a drug to the list of controlled substances. It’s nearly impossible for law enforcement to keep up. [With this bill], we were looking for a way to streamline it and cut down on that lag time.”

Advertise with us

Among those who voted “yes” was agreement on the bill’s simplicity and “common-sense” nature.

“This is a great step in making sure we’re in line with the federal government,” said Sen. Tracy Pennycuick, R-Berks/Montgomery.

Sen. Jim Brewster, D-Allegheny, was one of two Democrats voting to support the bill. He expressed frustration at the persistence of the opioid epidemic and a desire to try a new approach.

“One thing that never seems to get any better for us is the distribution of narcotics,” he said. “It’s killing people every day. … This is a logical approach to continue to attack the most lucrative business on the planet.”

He thought the vote should have been unanimous.

Advertise with us

But those who work directly with people who use drugs are begging for a different kind of solution, arguing that increased scheduling will only serve as a new flavor of the old War on Drugs, which many have argued did not curb drug use and exacerbated the problem.

“The Controlled Substances Act is a penalization tool, not a public health tool,” said Robert Ashford, executive director of Unity Recovery, a nonprofit for people to access recovery resources. The nonprofit has locations in Pittsburgh, Philadelphia and Weatherford, Texas.

“We need a radical rethinking of how we handle drug use. All this does is further punish people,” he said.

Ms. Scott said there’s an underlying issue with the method of scheduling. A drug receives a I through V classification, depending on what is deemed as its medical use and potential for abuse.

“The DEA is not a medical institution,” she said. “This has never been an effective strategy to combating drug use.”

Advertise with us

Mr. Ashford also noted the DEA’s past behavior in scheduling has at times seemed arbitrary to some: both cannabis and psilocybin have received Schedule I classification, deeming them as carrying zero medical benefit and a high potential for abuse, when researchers across the country have found both drugs to be less deadly than opioids and beneficial in treating chronic pain and PTSD, respectively.

“This is going to make everything worse,” said Ms. Scott.

Another major concern among opposers of the bill was the potential for classification thwarting research efforts of notable drugs, including one that has increasingly appeared in the illicit drug supply: xylazine.

According to the Pennsylvania Department of Health, xylazine contributed to 644 deaths across Pennsylvania in 2022 — an increase of more than 1000% since 2018. A veterinary tranquilizer, it is not approved for use in humans and leads to necrotizing wounds that can necessitate amputation. And, as xylazine is not an opioid, naloxone does not work to counteract it.

“We desperately need facts and information on what xylazine is doing to the human body,” said Ms. Scott. She is concerned that an increased scheduling will make the drug more difficult for researchers to obtain.

Advertise with us

The bill’s sponsors also directed attention to xylazine — colloquially known as tranq when mixed with fentanyl — as a novel player in the drug supply that has vexed law enforcement and muddied holding drug dealers accountable. (The drug received temporary classification of Schedule III in Pennsylvania by the state health department in June, and it was added to the list of controlled substances for one year).

About a quarter of Pittsburgh’s supply already contains the drug, Mr. Ashford estimated, based on his work in communities using drugs. It has increasingly shown up in death reports from the Allegheny County Medical Examiner’s office.

Ms. Baker said she hadn’t yet heard about concerns surrounding the potential impact of scheduling on research efforts. She and Mr. Robinson met with five district attorneys in Pennsylvania, and Ms. Baker said all of them supported the bill. They also met with the Office of the Attorney General.

The federal government, Mr. Robinson said, is in the best position to research new drugs entering the illicit supply.

“There’s no point in Pennsylvania having a duplicate effort,” he said. “The federal government has more resources than we do.”

Advertise with us

Mr. Brewster said that exceptions for researchers and veterinarians could be made in the form of an amendment, if research efforts become jeopardized.

The fate of the bill is not yet clear in the Democratic-controlled House. Rep. Jim Struzzi, R-Indiana, said he would support it. Rep. Struzzi lost a brother to addiction and has sponsored legalization of fentanyl and xylazine test strips, as well as supported syringe service programs around the state.

“I’m a big proponent of recovery, but there’s no path to recovery if you’re not alive,” he said. “It’s important to stop dealers before they’re able to provide these drugs to people who are addicted … This really has to be a complementary process. You have to have enforcement, and at the same time provide resources for recovery.”

Marianne Sinisi, an Altoona-based mother who lost her son to a fentanyl overdose in 2018, wants what she sees as criminalization of people using drugs to finally cease. Her son, Shawn Sinisi, was in and out of jail and rehab while trying to get sober, and she didn’t see the benefit that law enforcement had on getting him off drugs — in fact, she saw its harm.

“We just keep making bad choice after bad choice, and it’s not helping,” she said. “It’s like he died for nothing.”

Advertise with us

Ms. Baker said all the legislation does is create an expedited process to allow the rescheduling of controlled substances to realign with federal law, and for law enforcement response to enforce controlled substances to be similarly expedited.

“I view this as something that can protect citizens, not as going after someone in the throes of addiction,” she said.

Hanna Webster: hwebster@post-gazette.com